Honda Works Partner Aston Martin Aramco Formula One(TM) Team Unveils Livery of “AMR26” F1(TM) Machine Equipped with Honda Power Unit Ahead of the 2026 Race Season

TOKYO, Feb 10, 2026 - (JCN Newswire via SeaPRwire.com) - Ahead of the start of the 2026 FIA*1 Formula One World Championship (F1TM) season, Honda works partner Aston Martin Aramco Formula One™ Team (AMAF1), has unveiled the livery for its new F1 machine, the AMR26. Powered by the Honda F1…

Biologics License Application for Subcutaneous Formulation of “LEQEMBI(R)” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority Review in China

TOKYO and CAMBRIDGE, Mass., Feb 10, 2026 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector:…

CITIC Telecom CPC Wins Two Awards, Celebrating ‘Innovation Never Stops’ for 25 Years, recognizing Cybersecurity & Innovation Excellence

HONG KONG, Feb 9, 2026 - (ACN Newswire via SeaPRwire.com) – CITIC Telecom International CPC Limited (“CITIC Telecom CPC”), a wholly-owned subsidiary of CITIC Telecom International Holdings Limited (SEHK: 1883) is pleased to announce a triumph in winning two prestigious awards as 2026 unfolds, recognizing its cybersecurity and continuous innovation…

Establishment of the World’s First*1 Global Supply Chain to Introduce the Use of Renewable Plastics in Sony’s High-Performance Products

TOKYO, Feb 6, 2026 - (JCN Newswire via SeaPRwire.com) - Sony Corporation (Sony), Mitsubishi Corporation, ADEKA CORPORATION , CHIMEI Corporation, ENEOS Corporation, Formosa Chemicals & Fibre Corporation, Hanwha Impact Corporation, Idemitsu Kosan Co., Ltd., Mitsui Chemicals, Inc., Neste Corporation, Qingdao Haier New Material Development Co., Ltd., SK Geo Centric Co.,…

Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan

TOKYO and SHANGHAI, Feb 6, 2026 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Shanghai Henlius Biotech, Inc. (Headquarters: Shanghai, China, CEO: Jason Zhu, “Henlius”) announced today the conclusion of an exclusive commercialization and co-exclusive development and manufacturing license agreement for the anti-PD-1…

Fujitsu Japan and JMDC announce collaboration to build sustainable healthcare system in Japan through enhanced medical data utilization

Kawasaki and Tokyo, Japan, Feb 6, 2026 - (JCN Newswire via SeaPRwire.com) - Fujitsu Japan Limited and JMDC Inc. today announced the commencement of a collaboration aimed at advancing medical care and contributing to the establishment of a sustainable healthcare system in Japan.This collaboration, which began on January 5, leverages…

Genesys and Fujitsu Transform AEON Financial Service’s Contact Center Operations with Genesys Cloud Delivers Customers an Improved Self-Service Experience Resulting in Higher Completion and Reduced Wait Times

Tokyo and Kawasaki, Japan, Feb 6, 2026 - (JCN Newswire via SeaPRwire.com) - Genesys® Cloud Services, Inc. (Headquarters: Minato-ku, Tokyo; President: Paul Ito Ricci, hereinafter Genesys), a global cloud leader in AI-Powered Experience Orchestration, and Fujitsu Limited (Headquarters: Kawasaki City, Kanagawa Prefecture; President and CEO: Takahito Tokita; hereinafter Fujitsu) which…

TANAKA PRECIOUS METAL TECHNOLOGIES establishes total solutions system for contract manufacturing of various test kits including in vitro diagnostics

TOKYO, Feb 5, 2026 - (JCN Newswire via SeaPRwire.com) - TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd. (Head Office: Chuo-ku, Tokyo; Representative Director & CEO: Koichiro Tanaka), a company engaged in the industrial precious metals business of TANAKA, announced today that it has established a total solution system capable of supporting all…

Everest Medicines Announces Exclusive License Agreement with Micot to Commercialize MT1013

Shanghai, January 5, 2026 - (ACN Newswire via SeaPRwire.com) – Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an exclusive license agreement with Shaanxi Micot Pharmaceutical Technology Co.,…